Citigroup’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Citigroup’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-29,000	Closed	-$2.12M	–	5996
2024 Q3	$2.12M	Buy	+29,000	New	+$2.18M	﹤0.01%	2615
2022 Q2	–	Sell	-30,000	Closed	-$1.84M	–	6755
2022 Q1	$1.84M	Buy	+30,000	New	+$1.56M	﹤0.01%	2433
2016 Q4	–	Sell	-10,000	Closed	-$152K	–	7355
2016 Q3	$152K	Buy	+10,000	New	+$404K	﹤0.01%	4887

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Citigroup's ITCI Position: Q2 2025 in Review

Citigroup sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 202,695 shares — an estimated $26.7M sold.

Citigroup first reported a position in ITCI in Q2 2014 and held it in 44 quarters. The position peaked at $26.7M in Q1 2025. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Citigroup reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Citigroup sold 202,695 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $26.7M.
Citigroup first reported a position in Intra-Cellular Therapies Inc. in Q2 2014 and held it in 44 quarters.
Citigroup's Intra-Cellular Therapies Inc. position peaked at $26.7M in Q1 2025.
3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Citigroup's 13F filing for Q2 2025, filed 11 Aug 2025.